Approval covers 3 mg, 4 mg and 5 mg strengths of Janssen’s Balversa® equivalent for advanced urothelial carcinoma Previous Post Real time impact of volatility in margin requirements Next Post Markets clock biggest single-day gain since May 2025 as India-US trade deal sparks broad rally Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email, and website in this browser for the next time I comment.Post Comment
